All studies
CompletedPhase IIInterventional

XanaCIDD: A clinical study in which participants are randomly assigned to take either active drug or placebo (non active) to assess if the drug Xanamem is safe, tolerable and effective in helping adult patients with cognitive impairment due to depressive disorder

Living with depression can involve more than feeling low. Many people also struggle with 'brain fog', forgetfulness, and trouble concentrating, which can make daily life hard even when taking standard antidepressants. This trial, called XanaCIDD, is testing an experimental medicine named Xanamem to see if it can help improve these thinking and memory difficulties. Around 160 adults aged 18 to 70 across the UK and Australia will participate. Half will receive Xanamem tablets and half will receive a dummy pill (placebo) alongside their regular antidepressant for six weeks. Neither you nor the study team will know which tablet you receive. The whole study takes up to 14 weeks, including health checks, memory tasks, and follow-up reviews. Taking part is voluntary, and participants can leave the study at any point without it affecting their normal NHS care.

At a glance

Status
Completed
Phase
Phase II
Sponsor
Axiom Real-Time Metrics
Enrolment target
160
Start
15 Dec 2022
Estimated completion
19 Apr 2024

What is this study about?

Clinical depression is a common condition that affects how you feel, sleep, and cope with everyday life. Alongside sadness and low energy, many people experience frustrating problems with their thinking. This can include feeling mentally slowed down, having trouble focusing on work or reading, or finding it hard to remember everyday details. Standard antidepressants do not always improve these thinking and memory difficulties.

The XanaCIDD study is looking at whether a new medicine called Xanamem can safely improve these cognitive symptoms. Researchers want to find out if adding Xanamem to a person's usual antidepressant medicine helps clear brain fog, boost energy, and lift low mood more effectively than usual treatment alone.

To make sure the results are fair and reliable, participants will be put into one of two groups by chance. One group takes Xanamem, while the other takes a dummy tablet called a placebo that looks identical. Comparing these groups allows scientists to see clearly whether any improvements or side effects are truly caused by the study medicine.

Studies like this are an essential step in finding new, targeted treatments for depression. If successful, the research could lead to therapies that help people not only feel better emotionally, but also regain their mental sharpness and confidence in daily life.

Key takeaways

  • Tests a new medicine (Xanamem) to treat memory and concentration problems in depression.
  • Open to adults aged 18 to 70 who are already on a stable antidepressant.
  • Lasts up to 14 weeks, including 6 weeks of taking either Xanamem or a placebo.
  • Includes health checks, blood tests, and thinking assessments at a UK trial clinic.
  • Completely voluntary with the right to leave the study at any time.

Who may be eligible?

This study is designed for adults aged 18 to 70 who have been diagnosed with depression and are still experiencing persistent low mood together with noticeable trouble thinking, concentrating, or remembering. You must also have been taking a stable, steady dose of an approved antidepressant for at least six weeks before joining.

You will not be able to take part if you take certain specific types of antidepressants (such as tricyclic antidepressants, MAO inhibitors, or vortioxetine), or if you have recently had treatments like electroconvulsive therapy or magnetic brain stimulation. People who have a diagnosis of dementia, other major psychiatric conditions, or who are currently having active thoughts of suicide are also not eligible, as participant safety is the top priority.

If you smoke or vape, you may still be able to join as long as you use five or fewer cigarettes or nicotine products a day and agree to pause using them on days when your memory and thinking are tested.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you aged between 18 and 70?
  2. Have you been diagnosed with depression and currently feel low?
  3. Do you struggle with concentration, memory, or brain fog?
  4. Have you been on the same dose of your antidepressant for at least 6 weeks?
  5. Are you able to visit a study clinic for regular appointments over 14 weeks?
Answer every question to see your result.

What does participation involve?

Taking part in the trial lasts up to 14 weeks in total. First, there is a screening period of up to 4 weeks where doctors check your health to ensure the trial is safe for you. Next, you will take your assigned study tablets daily for 6 weeks, continuing alongside your usual antidepressant. Finally, there is a 4-week follow-up period to check on your wellbeing after you finish the tablets. You will attend visits at a local study clinic where staff will check your blood pressure, heart rate, and general health, and take routine blood tests. You will also complete questionnaires about your mood and do computer or paper tests to measure your memory and concentration. Rest breaks are always available if you feel tired during testing.

Potential risks and benefits

There is no guarantee that taking part will directly improve your health, but your participation helps scientists discover new ways to treat depression. Xanamem has already been tested in over 300 people in earlier studies without causing severe or life-threatening problems. The most common side effect reported is headache. Less common side effects include mild nausea, diarrhoea, feeling tired, dizziness, mild joint stiffness, or minor, temporary changes in liver blood tests. Clinic staff will keep a close eye on your health at every visit. Joining the study is completely your choice, and you can withdraw at any time without giving a reason and without affecting your routine NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • St. Pancras Clinical Research Ltd.
    City only
    London, England

Common questions

What is a placebo and why is it used?

A placebo is a harmless dummy pill that looks and tastes exactly like the study medicine but contains no active ingredients. It helps researchers prove whether the real medicine genuinely works better than chance.

Do I have to stop taking my normal antidepressant?

No. You will continue to take your regular antidepressant at your usual dose throughout the study, as long as it is on the list of approved medicines for the trial.

How long will I be involved in the study?

Your involvement lasts up to 14 weeks, which includes screening visits, 6 weeks of taking the trial tablets, and 4 weeks of follow-up health checks.

Can I leave the study early if I want to?

Yes. Participation is entirely voluntary. You can choose to stop taking part at any time, for any reason, and your regular doctor's care will not be affected.

Does taking part cost anything?

No. All study medication, medical tests, and clinic appointments related to the trial are provided free of charge.

How to find out more

Harinder Chera

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.